ArticleFrontiers in oncology2026
Regional lymph node metastasis as a risk factor for recurrence in Borrmann type II gastric cancer: particular significance of the no. 7 lymph node.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Borrmann classification is a well-established system for categorizing gastric cancer (GC). Although Borrmann type II GC is generally associated with favorable outcomes, a subset of patients still experiences recurrence with a poor prognosis. This study identified clinicopathological factors in Borrmann type II GC patients who are surgically targetable, with the aim of guiding gastrointestinal surgeons and improving patient prognosis. Methods: A total of 1,824 patients with GC who underwent radical gastrectomy at the First Affiliated Hospital of Sun Yat-sen University (2007-2019) were retrospectively analyzed, with an additional 197 patients from the First Affiliated Hospital of Shantou University Medical College (2014-2017) used for validation. Results: In the entire cohort, 440 patients (24.1%) were identified as having type II GC. Compared with other types of GC, type II GC is associated with more favorable overall survival. This subtype is characterized by a smaller tumor size and a lower incidence of serosal invasion and lymph node metastasis. Compared with nonrecurrent cases, recurrent cases more commonly involved tumors located in the upper stomach, demonstrated increased lymphatic spread, and were associated with more advanced pTNM staging. Notably, among the second-tier lymph node stations, tumor involvement of the No. 7 lymph nodes emerged as an important risk factor for recurrence. The peritoneum was the most frequent site of recurrence. Conclusions: Although type II GC patients usually have a favorable prognosis, disease recurrence dramatically impairs survival. Notably, the involvement of lymph node station No. 7 was an independent predictor of recurrence, indicating the need for meticulous lymphadenectomy and intensive postoperative surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.